Galera Therapeutics Inc.

Malvern, PA · Founded 2009 · Biotech · Acquired

Small molecule superoxide dismutase (SOD) mimetics, specifically GC4419, for preventing radiation-induced toxicities in cancer patients

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · galeratx.com

Sector: Biotech
Headquarters: Malvern, PA
Founded: 2009
Latest Form D: $205K, Apr 2011
Total capital: $2.8M

Federal grants: $2M; 3 awards · 2017–2020; Rank in peer group#29 of 502
Private capital raised: $885K; 2 Form D · last Apr 2011; 187 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Sep 2020Federal grantHealth and Human S · Phase II · GC4419, an SOD Mimetic, as a Radiomodulator in Lung Cancer Patients Treated with SBRT$869K
Sep 2020Federal grantHealth and Human S · Phase II · GC4419, an SOD Mimetic, as a Radiomodulator in Lung Cancer Patients Treated with SBRT$869K
Jun 2017Federal grantHealth and Human S · Phase II · GC4419, an SOD Mimetic, as a Radiomodulator in Lung Cancer Patients Treated with SBRT$225K
Apr 2011Private capital raisedForm D · SEC · 2nd filing$205K
May 2010Private capital raisedForm D · SEC · 1st filing$680K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

Federal grants#29 · top 6%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Jeffery L. KeeneResearcherExecutive OfficerLinked by $869K in grants as PI
Arthur T. FratamicoExecutive OfficerNamed in SEC Form D filings
Campbell A. MurrayDirectorNamed in SEC Form D filings
Catherine L. MatthesExecutive OfficerNamed in SEC Form D filings
Dennis L. RileyExecutive OfficerNamed in SEC Form D filings
Eric J. GulveDirectorNamed in SEC Form D filings

Show all 28 people

Frank A. TortiDirectorNamed in SEC Form D filings
Henry T. SkinnerDirectorNamed in SEC Form D filings
James A. BarrettDirectorNamed in SEC Form D filings
J. Mel SorensenExecutive Officer, DirectorNamed in SEC Form D filings
Joel J. SussmanExecutive OfficerNamed in SEC Form D filings
Jon T. HolmlundExecutive OfficerNamed in SEC Form D filings
J. Mel SorensenExecutive Officer, DirectorNamed in SEC Form D filings
Kevin LokayDirectorNamed in SEC Form D filings
Lawrence AllevaDirectorNamed in SEC Form D filings
Mel SorensenExecutive Officer, DirectorNamed in SEC Form D filings
Michael R. FriedmanDirectorNamed in SEC Form D filings
Michael A. PowellDirectorNamed in SEC Form D filings
Michael R. FriedmanDirectorNamed in SEC Form D filings
Michal A. SilverbergDirectorNamed in SEC Form D filings
Nancy T. ChangDirectorNamed in SEC Form D filings
Nancy T. ChangDirectorNamed in SEC Form D filings
Phillip L. BucklerExecutive OfficerNamed in SEC Form D filings
Randy W. WeissExecutive OfficerNamed in SEC Form D filings
Robert A. BeardsleyExecutive Officer, DirectorNamed in SEC Form D filings
Robert J. CalcaterraDirectorNamed in SEC Form D filings
Stephen T. RossExecutive OfficerNamed in SEC Form D filings
Thomas T. DyrbergDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

7 Hills Pharma LLCSimilar federal contract value in Biotech · null in contracts
AyuVis Research, Inc.Similar federal contract value in Biotech · null in contracts
EPOCH BIOTECH, LLCSimilar federal contract value in Biotech · null in contracts
REVERAGEN BIOPHARMA, INC.Similar federal contract value in Biotech · null in contracts
SCARLESS LABORATORIES INCSimilar federal contract value in Biotech · null in contracts
Nymirum, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.